Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01178 (oxytocin)
 15,767 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

During a one-year period, 838 nonstress tests, 425 nipple stimulation contraction stress tests (NS-CSTs), and 115 spontaneous CSTs were done. Results were compared to those of NSTs and CSTs done by classic methods during a previous one-year period. The results revealed no hyperstimulation from contraction stress testing with nipple stimulation, and a significant reduction in the time to perform both tests conducted simultaneously when compared to the nonstress test plus classic oxytocin challenge test. The time to perform the combined tests compared to the routine nonstress test was not significantly different. Moreover, a cost-saving was also demonstrated. The combination of the NST and nipple stimulation CST appeared to be safe, efficacious, and cost-effective.
 ...
PMID:Contraction stress test by nipple stimulation: efficacy and safety. 374 94

A prospective noncomparative study was designed to test the ability of the nonstress test (NST) and the contraction stress test or oxytocin challenge test (CST/OCT) to predict neonatal morbidity or impending mortality. Two hundred nine pregnancies tested within eight days of delivery were studied. The only two perinatal deaths occurred in association with the postmaturity syndrome, and both had a preceding reactive NST. Some patients (37.5%) with a positive CST/OCT had fetal distress in labor. Ninety-six percent of infants with distress in labor had an antecedent reactive NST. In the study, 25.8% of the patients had a major antepartum, intrapartum, or postpartum complication that was not predicted by the NST. Therefore, electronic antepartum fetal heart rate surveillance was used as only one facet of the overall patient analysis. Management of patients was based upon the combination of antepartum monitoring, real-time ultrasound evaluation of amniotic fluid, and placental morphology, as well as the clinical suspicion of increased risk (using fetal activity testing, etc).
 ...
PMID:Antepartum fetal heart testing: a clinical appraisal. 669 Oct 17

A total of 567 tests were performed in a 1 year period on 399 patients in an outpatient clinic setting to test the feasibility of an office approach to antepartum heart rate testing. Of these tests, 510 were reactive and 57 were nonreactive (NR); 15 NR tests had associated spontaneous CST's; 39 NR tests and one reactive test with an equivocal spontaneous CST were repeated in 2 to 4 hours; 30 tests were reactive and nine tests remained NR. An oxytocin-induced CST was needed to clarify fetal status in only nine of 607 tests. With this approach, the NST may be quite appropriate for office use.
 ...
PMID:Antepartum fetal heart rate testing. V. The nonstress test--an outpatient approach. 735 91

Among the methods of antepartum testing in use today, the nonprovocative tests (NST, BPP, MBPP) are safe and effective for use in ambulatory settings. Outpatient or office utilization of the CST is limited by the need for intravenous access (when oxytocin is used) and by the potential for uterine hyperstimulation and resultant acute FHR abnormalities. Regardless of the method of testing used, large studies have confirmed that the fetal death rate among patients undergoing antepartum testing is significantly lower than that in the general, untested population. This is a particularly encouraging observation in view of the fact that antepartum testing is used almost exclusively in complicated pregnancies at highest risk for poor outcome. In the future, protocols using adjunctive testing methods (fetal movement counting, fetal movement profile, Doppler velocimetry) in combination with standard methods (CST, NST, BPP, MBPP) may further reduce the incidence of fetal death in high-risk populations. At present, the beneficial effects of antepartum testing have created a situation in which the likelihood of fetal death in high-risk, tested populations is lower than that in low-risk, untested populations. This paradox will force us to consider the option of routine antepartum testing in all pregnancies.
 ...
PMID:Antepartum testing. 974 61